NASDAQ:BLUE

bluebird bio - BLUE Stock Forecast, Price & News

$7.83

-0.18 (-2.25%)

(As of 12/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $7.76
▼
$8.14
50-Day Range: $5.70
▼
$8.49
52-Week Range: $2.87
▼
$11.70

Volume: 2.63 million shs
Average Volume: 5.31 million shs
Market Capitalization: $649.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.88

bluebird bio MarketRank™ Forecast

Analyst Rating: Hold
1.89 Rating Score
Upside/Downside: 12.2% Downside
$6.88 Price Target
Short Interest: Healthy
23.24% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 15 Articles This Week
Insider Trading: Selling Shares
$9,493 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.18) to ($2.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

942nd out of 1,023 stocks

Biological Products, Except Diagnostic Industry

161st out of 170 stocks

0.9

Analyst's Opinion

Consensus Rating
bluebird bio has received a consensus rating of Hold. The company's average rating score is 1.89, and is based on 1 buy rating, 6 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.88, bluebird bio has a forecasted downside of 12.2% from its current price of $7.83.
Amount of Analyst Coverage
bluebird bio has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
23.24% of the outstanding shares of bluebird bio have been sold short.
Short Interest Ratio / Days to Cover
bluebird bio has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in bluebird bio has recently decreased by 14.51%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
bluebird bio does not currently pay a dividend.
Dividend Growth
bluebird bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLUE.

3.0

News and Social Media Coverage

News Sentiment
bluebird bio has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for bluebird bio this week, compared to 4 articles on an average week.
Search Interest
23 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 156% compared to the previous 30 days.
MarketBeat Follows
27 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,493.00 in company stock.
Percentage Held by Insiders
Only 2.20% of the stock of bluebird bio is held by insiders.
Percentage Held by Institutions
78.25% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for bluebird bio are expected to grow in the coming year, from ($4.18) to ($2.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of bluebird bio is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of bluebird bio is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
bluebird bio has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About bluebird bio (NASDAQ:BLUE) Stock

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Stock News Headlines

December 2, 2022 | marketbeat.com

Why CSL Ltd Stock Could Be Worth a Look (BLUE)

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

December 7, 2022 | americanbankingnews.com

FY2022 EPS Estimates for bluebird bio, Inc. Raised by Wedbush (NASDAQ:BLUE)

December 6, 2022 | americanbankingnews.com

Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $6.88

December 6, 2022 | americanbankingnews.com

Research Analysts Set Expectations for bluebird bio, Inc.'s FY2022 Earnings (NASDAQ:BLUE)

December 4, 2022 | americanbankingnews.com

Head to Head Contrast: Cardiol Therapeutics (NASDAQ:CRDL) vs. bluebird bio (NASDAQ:BLUE)

November 30, 2022 | bloomberg.com

Bluebird Bio to Receive Much-Needed Cash Infusion From Fast Pass Sale

November 30, 2022 | msn.com

Looking Into bluebird bio's Return On Capital Employed

November 30, 2022 | finance.yahoo.com

Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

November 30, 2022 | finance.yahoo.com

bluebird bio Sells Priority Review Voucher for $102 Million

November 28, 2022 | seekingalpha.com

bluebird bio: Close To Approval But In A Precarious Position

November 26, 2022 | marketwatch.com

Sickle Cell Disease Treatments Market 2022 : Opportunities in Future, Business Growth Analysis by Top Countries Data and Industry Players by 2028

November 25, 2022 | marketwatch.com

What is a Revenue Expectation of Gene Therapy Market to 2025?

November 17, 2022 | finance.yahoo.com

2 Growth Stocks That Could Double in 2023

November 8, 2022 | nasdaq.com

bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates

November 7, 2022 | marketwatch.com

Bluebird Bio Names Chris Krawtschuk Chief Financial Officer >BLUE

November 7, 2022 | msn.com

Recap: bluebird bio Q3 Earnings

November 2, 2022 | finance.yahoo.com

bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference

November 2, 2022 | finance.yahoo.com

Earnings Preview: Fstar Therapeutics, Inc. (FSTX) Q3 Earnings Expected to Decline

October 26, 2022 | seekingalpha.com

bluebird bio: Commercial Success Highly Uncertain

October 25, 2022 | marketwatch.com

Advanced Therapy Medicinal Products Market Is Likely to Experience a Massive Growth in Near Future - Report Spread across 96 Pages

October 21, 2022 | finance.yahoo.com

bluebird bio, Inc. (BLUE)

October 4, 2022 | fool.com

Should You Buy the Dip With Bluebird Bio?

October 4, 2022 | finance.yahoo.com

Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy

October 3, 2022 | finance.yahoo.com

Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future

October 3, 2022 | nz.finance.yahoo.com

bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Company Calendar

Last Earnings: 11/05/2021
Today: 12/06/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/03/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BLUE
CUSIP: N/A
CIK: 1293971
Web: www.bluebirdbio.com
Phone: (339) 499-9300
Fax: N/A
Employees: 518
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.88
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: -12.2%
Consensus Rating: Hold
Rating Score (0-4): 1.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-819,380,000.00
Net Margins: -8,828.28%
Pretax Margin: -8,384.38%
Return on Equity: -173.58%
Return on Assets: -77.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.27
Quick Ratio: 1.27

Sales & Book Value

Annual Sales: $3.66 million
Price / Sales: 177.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.34 per share
Price / Book: 1.47

Miscellaneous

Outstanding Shares: 82,910,000
Free Float: 81,086,000
Market Cap: $649.19 million
Optionable: Optionable
Beta: 0.98

Key Executives

Mr. Andrew Obenshain (Age 47)
Pres, CEO & Director
Comp: $842.85k

Mr. Thomas J. Klima (Age 50)
Chief Commercial Officer & COO
Comp: $509.7k

Mr. Christopher Krawtschuk CPA (Age 48)
CFO, Principal Accounting Officer & Treasurer

Ms. Elizabeth Pingpank
Director of Corp. Communications

Sarah Alspach
Chief Communications Officer

Ms. Andrea Walton
Chief People Officer

Dr. Liviu Niculescu M.D.
Ph.D., Sr. VP of Global Medical Affairs

Ms. Melissa Bonner
Sr. VP of Research

Mr. Richard Colvin M.D.
Ph.D., Chief Medical Officer

Mr. Kasra Kasraian
Sr. VP of Technical Devel. & Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BLUE Stock - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.
What is bluebird bio's stock price forecast for 2023?: 9 Wall Street research analysts have issued 1-year price objectives for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's stock price to reach $6.88 in the next twelve months. This suggests that the stock has a possible downside of 12.2%.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.
How have BLUE shares performed in 2022?: bluebird bio's stock was trading at $9.99 at the beginning of the year. Since then, BLUE stock has decreased by 21.6% and is now trading at $7.83.
View the best growth stocks for 2022 here.
Are investors shorting bluebird bio?: bluebird bio saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 19,270,000 shares, a decline of 14.5% from the October 31st total of 22,540,000 shares. Based on an average trading volume of 6,040,000 shares, the days-to-cover ratio is currently 3.2 days.
View bluebird bio's Short Interest.
When is bluebird bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 3rd 2023.
View our BLUE earnings forecast.
How were bluebird bio's earnings last quarter?: bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings results on Friday, November, 5th. The biotechnology company reported ($3.16) earnings per share for the quarter, missing the consensus estimate of ($2.65) by $0.51. The biotechnology company had revenue of $22.70 million for the quarter, compared to analysts' expectations of $39.07 million. bluebird bio had a negative trailing twelve-month return on equity of 173.58% and a negative net margin of 8,828.28%. The company's revenue was up 17.6% on a year-over-year basis. During the same period last year, the company earned ($2.94) EPS.

What is Nick Leschly's approval rating as bluebird bio's CEO?: 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.
What other stocks do shareholders of bluebird bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).
What is bluebird bio's stock symbol?: bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."
Who are bluebird bio's major shareholders?: bluebird bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (15.34%), BlackRock Inc. (8.32%), Tang Capital Management LLC (7.64%), Vanguard Group Inc. (4.47%), Credit Suisse AG (1.91%) and Dimensional Fund Advisors LP (1.96%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Philip D Gregory, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends.
How do I buy shares of bluebird bio?: Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is bluebird bio's stock price today?: One share of BLUE stock can currently be purchased for approximately $7.83.
How much money does bluebird bio make?: bluebird bio (NASDAQ:BLUE) has a market capitalization of $649.19 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($6.10) on an earnings per share basis.
How many employees does bluebird bio have?: The company employs 518 workers across the globe.
How can I contact bluebird bio?: bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.

This page (NASDAQ:BLUE) was last updated on 12/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial